Symbol | Exchange | Currency |
|---|
March 18 (Reuters) - Auscann Group Holdings Ltd AC8.AX :* CANNPAL ANIMAL THERAPEUTIC IMPLEMENTED SCHEME UNDER WHICH CANNPAL SHAREHOLDERS GOT 1.3 SHARES IN CO FOR EVERY 1 SHARE...
Feb 22 (Reuters) - Auscann Group Holdings Ltd AC8.AX :* CHARLES ALTSHULER WILL BE APPOINTED CHIEF FINANCIAL OFFICER
Jan 8 (Reuters) - Auscann Group Holdings Ltd AC8.AX :* AUSCANN LEADERSHIP POST CANNPAL ACQUISITION,CP1-AC8.AX* NICK WOOLF HAS DECIDED TO TENDER HIS RESIGNATION AS CEO* NICK...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Sell | Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Sell | Neutral | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.92 | 4.95 | 4.90 | -0.02 | -0.40% | 612.60K | Sydney | |||
| 24.30 | 24.33 | 23.39 | +1.340 | +5.84% | 1.66M | Sydney | |||
| 12.89 | 12.92 | 12.77 | -0.01 | -0.04% | 350.76K | Sydney | |||
| 1.09 | 1.14 | 1.09 | -0.02 | -1.80% | 684.71K | Sydney | |||
| 5.10 | 5.18 | 5.10 | -0.050 | -0.97% | 97.32K | Sydney | |||
| 15.99 | 16.06 | 15.81 | +0.33 | +2.11% | 430.51K | Sydney | |||
| 0.059 | 0.00 | 0.00 | 0.000 | 0.00% | 788.90K | Sydney | |||
| 1.71 | 1.735 | 1.705 | +0.005 | +0.29% | 5.67M | Sydney | |||
| 28.67 | 29.19 | 28.22 | -0.63 | -2.15% | 27.77K | Sydney | |||
| 12.90 | 12.91 | 12.71 | +0.150 | +1.18% | 330.19K | Sydney | |||
| 2.17 | 2.20 | 2.14 | 0.00 | 0.00% | 528.19K | Sydney | |||
| 1.045 | 1.045 | 1.01 | +0.005 | +0.48% | 91.28K | Sydney | |||
| 0.57 | 0.00 | 0.00 | -0.01 | -1.71% | 230.38K | Sydney | |||
| 7.77 | 7.79 | 7.71 | +0.07 | +0.91% | 144.35K | Sydney | |||
| 0.128 | 0.00 | 0.00 | -0.008 | -5.56% | 5.28M | Sydney |
AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.
